KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $245.5 million.

  • Emergent BioSolutions' Cash & Equivalents rose 6377.59% to $245.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.5 million, marking a year-over-year increase of 6377.59%. This contributed to the annual value of $99.5 million for FY2024, which is 1092.21% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Cash & Equivalents of $245.5 million as of Q3 2025, which was up 6377.59% from $267.3 million recorded in Q2 2025.
  • Emergent BioSolutions' Cash & Equivalents' 5-year high stood at $642.6 million during Q4 2022, with a 5-year trough of $69.7 million in Q2 2024.
  • For the 5-year period, Emergent BioSolutions' Cash & Equivalents averaged around $285.8 million, with its median value being $245.5 million (2025).
  • Per our database at Business Quant, Emergent BioSolutions' Cash & Equivalents tumbled by 8261.75% in 2023 and then skyrocketed by 28350.07% in 2025.
  • Emergent BioSolutions' Cash & Equivalents (Quarter) stood at $576.1 million in 2021, then rose by 11.54% to $642.6 million in 2022, then plummeted by 82.62% to $111.7 million in 2023, then dropped by 10.92% to $99.5 million in 2024, then skyrocketed by 146.73% to $245.5 million in 2025.
  • Its Cash & Equivalents was $245.5 million in Q3 2025, compared to $267.3 million in Q2 2025 and $149.1 million in Q1 2025.